Developing New Product Applications

1
(No Transcript)
2
Meridian At a Glance

• Company founded in 1977 IPO in 1986
• Headquartered in Cincinnati, OH
• 400 Employees
• Operating Segments
• US Diagnostics (61 of 2006 net sales)
• European Diagnostics (18 of 2006 net sales)
• Life Science (21 of 2006 net sales)
• BIODESIGN
• O.E.M. Concepts
• Viral Antigens
• Meridian Biologics
• Products sold in over 60 countries through 42
  direct sales reps and 100 distributors
• 2006 net sales of 108 million, EBITDA of 32
  million and Net Income of 18 million

3
Product Development

• Develop 3-5 new diagnostic products from core
  technologies each year
• Focus on high-value market opportunities for
  rapid detection of acute infectious diseases
  influenza, stomach ulcers, rotavirus
• Application of variety of simple, rapid
  technologies to satisfy any labs workflow
• Full integration of RD, manufacturing, and
  distribution to access over 60 global markets

4
ExampleTarget Clostridium difficile bacteria

• Impacts patients receiving antibiotics in
  hospitals
• Patients become infected following contact with
  C. difficile spores
• Cell-destroying toxins are released in nearly 40
  of infections
• Severe colitis results, due to perforation and
  destruction of intestinal cell walls

Medical need Fast diagnosis of toxins followed
by rapid treatment decisions
5
Meridians Innovative SolutionImmunoCard
Toxins AB

• Rapid, single-unit diagnostic test
• Detects all clinically significant C. difficile
  toxins
• Color-change results in just minutes
• Enables rapid test and treat response

6
Consistent, Innovative Product Development
49 new products developed since 1991
1990 Meritec C. difficile
1991 Premier C. difficile Toxin A
1993 ImmunoCard C. difficile
1996 ImmunoCard C. difficile Toxin A
1999 Premier Toxins AB
2004 ImmunoCard Toxins AB